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Background: The study of the association between genotype and phenotype is of great importance for the
prediction of multiple diseases and pathophysiological conditions. The relationship between angiotensin converting
enzyme (ACE) Insertion/Deletion (I/D) polymorphism and Familial Hypercholesterolemia (FH) has been not fully
investigated in all the ethnicities. In this study we sought to determine the frequency of I/D polymorphism
genotypes of ACE gene in Saudi patients with FH.
Results: This is a case–control study carried out purely in Saudi population. Genomic DNA was isolated from 128
subjects who have participated in this study. ACE gene I/D polymorphism was analyzed by polymerase chain
reaction in 64 FH cases and 64 healthy controls. There was no statistically significant difference between the groups
with respect to genotype distribution. Furthermore, we did not find any significant difference in the frequency of
ACE I/D polymorphism in FH subjects when stratified by gender (p = 0.43).
Conclusion: Our data suggest that ACE gene I/D polymorphism examined in this study has no role in predicting
the occurrence and diagnosis of FH.
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Familial hypercholesterolemia (FH, OMIM 143890) is an
inherited disorder of lipoprotein metabolism, transmit-
ted in an autosomal dominant manner and clinically
characterized by elevated serum levels of total and low-
density lipoprotein (LDL) cholesterol, the presence of
tendon xanthomas and premature atherosclerosis [1].
The genetic basis of FH is a large array of mutations in
the LDL-receptor (LDLR) gene (OMIM 606945), re-
sulting in a lack of functional receptors for LDL on the
liver cell surface, giving rise to increased plasma LDL
levels [2]. Population frequency of heterozygous familial* Correspondence: imkhan@ksu.edu.sa
†Equal contributors
1Department of Clinical Laboratory Sciences, College of Applied Medical
Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Kingdom of
Saudi Arabia
Full list of author information is available at the end of the article
© 2013 Alharbi et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.hypercholesterolemia (hFH) is approximately 1/500. Al-
though genetically the disease is caused by mutations in
the LDLR gene, the clinical phenotype of FH can vary
regardless of the mutation and this variability is assumed
to be due to both environmental and genetic factors [3].
The clinical phenotype caused by mutations in LDLR,
APOB or PCSK9 and characterized by elevated levels of
plasma LDL-Cholesterol (LDL-C) is currently referred to
as Autosomal Dominant Hypercholesterolemia (ADH,
OMIM 603776) [1].
Gene polymorphisms are markers of biologic diversity,
and some genotypic variations correlate with specific
phenotypes relevant to the human diseases. However, it
is not clear whether many of these variants are involved
in the pathogenesis of diseases or are merely in proximity
to other pathogenic genetic factors-a phenomenon known
as linkage disequilibrium. Angiotensin-converting enzymeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Figure 1 Identification of ACE I/D polymorphism in 2.5%
agarose gel electrophoresis. Legend: Lane 1: 50bp DNA Marker/
Ladder. Lane 2&6: Homozygous II genotype (490 bp). Lane 3&5:
Homozygous DD genotype (190 bp). Lane 4: Heterozygous ID
genotype (490/190 bp).
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sponsible for inter individual differences in ACE plasma
levels. It is known that the frequency of ACE D alleles var-
ies in different ethnic groups [4]. A previous study by
O'Malley et al. [5] have shown an association with FH pa-
tients who have myocardial infarction (MI) and coronary
heart disease (CHD) [5]. I/D polymorphism have also been
associated with risk of MI [6]. ACE gene is involved in the
conversion of Angiotensin I to Angiotensin II by its metal-
loproteinase enzymatic activity. It plays a major role in the
rennin–angiotensin (RAS) system. I/D polymorphism
(Consisting of a 287-bp fragment) in intron 16 of the gene
has been related to the amount of circulating enzyme. In-
dividuals homozygous for the deletion have an approxi-
mately two-fold higher level of circulating enzyme in
comparison to individuals homozygous for the insertion
[7]. Angiotensin II increases vascular smooth muscle cell
proliferation, monocyte adhesion, platelet adhesion and
aggregation. ACE genotype acting through the tissue or
possible plasma ACE concentrations has been implicated
in the aetiology of the disease [8].
ACE is a zinc metalloprotease that is widely distrib-
uted on the surface of epithelial and endothelial cells. Its
gene consists of 26 exons and spans 21 kb on the human
chromosome 17. The sequence codes a 1306-amino-acid
protein, including a signal peptide. It has a common
polymorphism that consists of the presence (I allele) or
the absence (D allele) of a 287-bp Alu repeat sequence
within intron 16. Although the I/D polymorphism is in
the intronic region of the ACE gene, studies have shown
that the DD genotype is strongly associated with in-
creased plasma or serum ACE levels [9]. ACE activity in
individuals with DD genotype is twice that found in
those with II genotypes. Subjects with ID genotype ex-
hibit intermediate levels of ACE [7]. This ACE I/D gene
polymorphism has been implicated as a risk factor for a
number of pathologies, such as MI, stroke, Type 2 Dia-
betes Mellitus (T2DM), Diabetic Nephropathy (DN),
and hypertension in different ethnic groups, but these
findings are far from conclusive [4,10]. The aim of this
study was to analyze whether the ACE gene I/D poly-
morphism is associated with the FH patients in Saudi
population.
Materials and methodology
In this study 64 subjects diagnosed with FH, based on
the Deutch working group classification criteria [11].
Patients were recruited from outpatient clinic at King
Khalid University Hospital (KKUH), Riyadh. Healthy vo-
lunteers (n = 64) were recruited from Medical and la-
boratory staff at KKUH, and individuals attend KKUH
for routine checkup and who were not having chronic
metabolic/ medical disease. The research protocol was
approved by the Institutional Review Board at KKUH(E-12-829). All participants provided written informed
consent prior to enrollment into the study.
Blood
Participants were advised to fast overnight for at least
10 hours prior to sample collection. Five mL of blood
sample was collected from every participant; 3 mL of the
serum sample was used for biochemical parameters like
Total Cholesterol (TC), Triglycerides (TG), HDL-C and
LDLC to confirm the FH and 2 mL of EDTA blood sam-
ple was used for molecular investigation.
Biochemical analysis
Serum samples of TC and TG were measured by the
standard enzymatic method (Pars Azmon kit, Iran) using
an automated RA-1000 (Technicon, USA). Serum LDL-C
and HDL-C levels were measured using commercially
available enzyme assay kits (Pars Azmon kit, Iran).
Genomic DNA isolation and genotyping of ACE I/D
polymorphism
The blood samples which were collected in the EDTA
tubes were used for extraction of DNA from the peri-
pheral blood leukocytes. Genomic DNA was extracted
by standard protocol [12] with Norgen DNA extraction
kit (Norgen Biotek corp, Canada). Extracted DNA was
quantified by NanoDrop to the DNA concentration.
ACE genotypes were determined by Polymerase Chain
reaction (PCR) analysis as described in our previous
work [12]. Specific oligonucleotide primers: forward pri-
mer of 5′CTGGAGACCACTCCCATCCTTTCT-3′ and
the reverse primer of 5′- GATGTGGCCATCACATTC
GTCACGAT-3′ were applied to acquire a 490 bp DNA
fragment in intron 16. The amplification was carried out
in a total volume of 20 μL reaction mixture contain
10 μM of each primer, 6 μL of sterile water and 10 μL of
Table 1 Demographic characteristics and biochemical
profile of FH patients and healthy control
S. no FH cases Healthy
controls
p value
(n = 64) (n = 64)
1 Age (Years) 52.06 ± 10.27 44.8 ± 6.87 p = 0.0001
2 Gender: Male/Female 20:44 22:42 p = 0.7
3 TG (mmol/L) 1.3 ± 0.50 1.1 ± 0.36 p = 0.01
4 TC (mmol/L) 6.4 ± 0.68 4.6 ± 0.39 p = 0.04
5 HDL-C (mmol/L) 1.4 ± 0.24 0.9 ± 0.21 p = 0.55
6 LDL-C (mmol/L) 4.8 ± 0.55 3.1 ± 0.32 p = 0.01
Table 3 Statistical analysis for FH individuals
S. no Genotypes Odds ratio
1 DD Vs ID + II OR-1.465;95% CI = 0.7265–2.956; p = 0.28
2 ID + DD Vs II OR-1.696;95% CI = 0.7385–3.893; p = 0.21
3 ID Vs II + DD OR-1.00;95% CI = 0.4781–2.091; p = 0.85
4 D Vs I OR-1.481;95% CI = 0.8953–2.449; p = 0.12
Table 4 Genotype and allele frequency of ACE gene
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dNTPs, 10 units of Taq DNA polymerase (Norgen Bio-
tek corp, Canada) and the 60 ng template DNA. The
PCR was performed in a thermal cycler (Applied Bio-
systems, Hercules, California, USA). The cycling and
amplification conditions were as follows; an initial de-
naturation was set up for 5 minutes at 95°C followed by
35 cycles of denaturation for 30 seconds at 95°C, anneal-
ing for 30 seconds at 59°C, extension for 45 seconds at
72°C and the final extension was at 72°C for 5 minutes.
The insertion band is considered as 490 bp which repre-
sents the I allele and 190 bp is identified as deletion
band (without 287-bp Alu insertion) which represents
the D allele and the I/D band was 490/190 bp which is
considered as the heterozygous (Figure 1). The amplified
PCR products were clearly separated on 2.5% agarose
gel with ethidium bromide stained (Cambrex, East
Rutherford, NJ, USA) and visualized on a transillumi-
nator (Dafco, USA).
Statistical analysis
All the statistical analyses were carried out using SPSS
(Chicago, IL, USA) software version 19.0 for Microsoft
Windows®. Clinical characteristics of all subjects were
expressed as mean ± SD. Continuous variables were
compared between the groups using two-tailed student’s
t test. Significant cutoff was set at 0.05. Crude ORs with
95% CIs were used to evaluate the strength of the associ-
ation between ACE I/D polymorphism and FH. Pooled
ORs were calculated for allelic contrast (D vs. I), domi-
nant (DD +DI vs. II) and recessive (DD vs. ID + II) gen-
etic model. Z-test was used to determine the significanceTable 2 Genotype and allele frequency of ACE gene
Genotypes and Alleles FH cases (n = 64) Healthy controls (n = 64)
II 12 (18.7) 18 (28.1)
ID 21 (32.8) 21 (32.9)
DD 31 (48.4) 25 (39)
I 45 (0.35) 57 (0.45)
D 83 (0.65) 71 (0.55)of the pooled ORs, and p value < 0.05 was considered
significant. The effect of I/D genotypes of ACE gene was
analyzed using general linear model ANOVA for clinical
characteristics. A level of p <0.05 was considered statisti-
cally significant.
Result
The demographic and the biological data of all the pa-
tients participating in this study are shown in Table 1.
The lipid profile parameters used in this study are fast-
ing TC, TG, HDL-C and LDL-C. TG, TC and HDL-C
levels in the FH group were 1.3 ± 0.50 mmol/L, 6.4 ±
0.68 mmol/L and 1.4 ± 0. 24 mmol/L compared to 1.1 ±
0.36 mmol/L, 4.6 ± 0.39 mmol/L and 0.9 ± 0.21 mmol/L
in the control group (p < 0.05). The LDL-C level was
4.8 ± 0.55 mmol/L in FH individuals compared to 3.1 ±
0.32 mmol/L in the control group (p > 0.05). There was
significant difference in the Age, TG, TC and LDL-C
levels between the FH subjects and the healthy controls
(p < 0.05), but there was no difference between FH sub-
jects and healthy controls in HDL-C and gender (p > 0.05).
Screening of I/D polymorphism in the ACE gene
The distribution of ACE I/D polymorphism among FH
individuals is shown in Table 2. The frequencies of ACE
DD, ID and II genotypes among FH patients were 48.4%,
32.8% and 18.7% respectively. The percentage of D allele
was 0.65% and of that of I allele was 0.35%. In the
control subjects, the distribution of ACE DD, ID and II
genotypes was 39%, 32.9% and 28.1% respectively. The
allele frequencies was 0.55% and 0.45% for the D and I
alleles, respectively. When we compared the frequency
of ACE DD genotypes and D allele in FH cases with
healthy controls, the difference was not statistically







OR (95% CI) p value
II 4 (20%) 8 (18.2%) 0.6087 (0.2083–1.779) p = 0.36
ID 8 (40%) 13 (29.5%) 1.59 (0.5629–4.797) p = 0.40
DD 8 (40%) 23 (52.3%) 0.8889 (0.2335–3.384) p = 0.86
I 16 (0.4) 29 (0.33) Ref
D 24 (0.6) 59 (0.67) 0.7373 (0.3403–1.597) p = 0.43
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Similarly, we did not find any significant difference in
the D allele frequencies between patients and controls
(Table 3). We also explored the association between
ACE I/D polymorphism and FH according to gender
and found no significant difference, OR = 0.7373, p = 0.43
(95% CI = 0.3403-1.597) (Table 4).
Discussion
To the best of our knowledge this is the first study to in-
vestigate the association of ACE gene I/D polymorphism
and FH in Saudi population. In our study FH individuals
tended to have higher DD (48.4%) genotypes and more
ID (32.9%) genotypes than controls. However, there was
no significant difference in the allelic frequency between
the patients and controls.
Previous studies addressing the association between
FH and ACE gene polymorphism focused on the poten-
tial risk of CHD coronary heart disease associated with
ACE gene polymorphism in FH patients. For example,
O’Malley et al. [5] showed that in heterozygote FH pa-
tients with ACE-DD genotype, the incidence of MI is 2.5
times higher and CHD is 2.2 higher than in those with
DI or II genotypes. On the other hand, another study
[13], did not find any association between ACE gene de-
letion/insertion polymorphism and increased risk of
CHD in patients with FH.
A few studies have been conducted in Saudi Arabia
and Middle East looking at the association between ACE
gene polymorphism and certain diseases. We have repor-
ted previously an association between ACE gene poly-
morphism and G6PD deficiency [12]. El-Hazmi et al. [14]
also showed a significant association between ACE DD
genotype and obesity among Saudi patients.
In contrary to that, Dzimiri et al. [15] showed no asso-
ciation between ACE genotype and risk of coronary ar-
tery disease in Saudi patients. Another study reported by
Chmaisse et al. [16] showed no association between
T2DM and ACE gene polymorphism in s mall Lebanese
cohort. Our study is limited by small sample size and
the fact that our patients have no documented coronary
heart disease which may explain our inability to show an
association between ACE gene polymorphism and FH.
Conclusion
In conclusion, our study has not shown an association
between I/D polymorphism of ACE gene and FH in the
Saudi populations. However, considering the relatively
small sample sizes of our study, a firm conclusion cannot
be made and larger studies in more well-characterized
subjects should be conducted in the future.
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